CLINICAL TRIALS PROFILE FOR COMIRNATY
✉ Email this page to a colleague
All Clinical Trials for COMIRNATY
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT04860739 ↗ | Vaccination With COMIRNATY in Subjects With a VAXZEVRIA First Dose | Active, not recruiting | Instituto de Salud Carlos III | Phase 2 | 2021-04-24 | CombiVacS is a phase 2 randomized, adaptive trial developed to evaluate the immunogenicity of a dose of COMIRNATY after a previous single dose of VAXZEVRIA. A stratification will be made based on the following factors: study site, sex and age. This protocol allows to test the immunogenicity and safety of a heterologous vaccination strategy after a previous single dose of VAXZEVRIA. |
| NCT04860739 ↗ | Vaccination With COMIRNATY in Subjects With a VAXZEVRIA First Dose | Active, not recruiting | Spanish Clinical Research Network - SCReN | Phase 2 | 2021-04-24 | CombiVacS is a phase 2 randomized, adaptive trial developed to evaluate the immunogenicity of a dose of COMIRNATY after a previous single dose of VAXZEVRIA. A stratification will be made based on the following factors: study site, sex and age. This protocol allows to test the immunogenicity and safety of a heterologous vaccination strategy after a previous single dose of VAXZEVRIA. |
| NCT04951323 ↗ | Impact of the Immune System on Response to Anti-Coronavirus Disease 19 (COVID-19) Vaccine in Allogeneic Stem Cell Recipients (Covid Vaccin Allo) | Recruiting | Pfizer | Phase 3 | 2021-03-22 | The present study is a prospective phase IV study. All participants will receive the anti-Coronavirus Disease 2019 (COVID-19) Vaccine (messenger Ribonucleic acid-based vaccine, BNT162b2 or Comirnaty®, commercialized by Pfizer-BioNTech) being authorized in the European Union since December 2020. The vaccine is administered intramuscularly after dilution as a series of two doses at least 21 days apart. |
| NCT04951323 ↗ | Impact of the Immune System on Response to Anti-Coronavirus Disease 19 (COVID-19) Vaccine in Allogeneic Stem Cell Recipients (Covid Vaccin Allo) | Recruiting | University of Liege | Phase 3 | 2021-03-22 | The present study is a prospective phase IV study. All participants will receive the anti-Coronavirus Disease 2019 (COVID-19) Vaccine (messenger Ribonucleic acid-based vaccine, BNT162b2 or Comirnaty®, commercialized by Pfizer-BioNTech) being authorized in the European Union since December 2020. The vaccine is administered intramuscularly after dilution as a series of two doses at least 21 days apart. |
| NCT05077254 ↗ | COVID Protection After Transplant-Immunosuppression Reduction | Not yet recruiting | PPD | Phase 2 | 2021-11-01 | This study will enroll individuals who have: - Completed, at a minimum, a full 2-dose course of either the Moderna messenger RNA (mRNA) based coronavirus infectious disease 19 (COVID-19) vaccine or the Pfizer-BioNTech mRNA based COVID-19 vaccine, and - A negative or indeterminate (<0.8 U/mL) antibody response measured at least 30 days after the last dose of vaccine. This group of patients is at high risk for severe COVID-19 disease due to pharmacologic immunosuppression and a high prevalence of non-transplant risk factors such as obesity and diabetes. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for COMIRNATY
Condition Name
Clinical Trial Locations for COMIRNATY
Trials by Country
Clinical Trial Progress for COMIRNATY
Clinical Trial Phase
Clinical Trial Sponsors for COMIRNATY
Sponsor Name
